A traditional Chinese medicine composition for treating gastrointestinal dysfunction in patients undergoing chemotherapy for gastric cancer and its uses.
By using acupoint application of a combination of traditional Chinese medicine such as Inula japonica, the problem of gastrointestinal dysfunction caused by chemotherapy was solved, gastrointestinal symptoms and quality of life were improved, and a non-invasive and effective treatment method was provided.
Patent Information
- Application Number
- CN202411678774.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-22
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-11-22
AI Technical Summary
Chemotherapy-induced gastrointestinal dysfunction is severe in patients with advanced gastric cancer. Current traditional Chinese medicine treatments are mostly oral decoctions, which are difficult to apply, and there are no literature reports on external application of traditional Chinese medicine compositions.
A traditional Chinese medicine composition consisting of Inula japonica, Zingiber officinale, Clove, Persimmon calyx, Dalbergia odorifera, Areca catechu, Areca peel, Lindera strychnifolia, Radish seed, and processed rhubarb is used to make acupoint patches, which are applied to acupoints such as Shenque, Neiguan, and Zusanli to treat gastrointestinal dysfunction.
It significantly improves gastrointestinal symptoms during chemotherapy, such as nausea, vomiting, and constipation, thereby improving patients' quality of life and improving compliance.
Abstract
Description
Technical Field
[0001] This invention relates to a traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy in patients with gastric cancer and its application. Background Technology
[0002] The main treatment for patients with advanced gastric cancer is a comprehensive approach combining chemotherapy, targeted therapy, and immunotherapy. Although targeted and immunotherapies have shown good efficacy in treating gastric cancer in recent years, these treatments often need to be combined with chemotherapy. Therefore, chemotherapy remains the cornerstone of gastric cancer treatment.
[0003] Chemotherapy often causes gastrointestinal dysfunction in patients, such as nausea, vomiting, and constipation. The stomach is an important digestive and absorptive organ, and stomach cancer patients often experience symptoms such as bloating, stomach pain, nausea, and vomiting. Chemotherapy exacerbates these digestive problems, further affecting the patient's diet and nutrient absorption, often preventing the chemotherapy from proceeding as planned.
[0004] Traditional Chinese medicine (TCM) treatment for gastric cancer is characterized by syndrome differentiation and treatment based on TCM principles, with oral decoctions being the primary method. However, gastric cancer patients undergoing chemotherapy often experience gastrointestinal dysfunction, making oral administration of decoctions difficult. Therefore, the advantages of external TCM treatments are becoming increasingly apparent. Compared to oral medications, external application of Chinese herbal medicine can significantly reduce the burden on the patient's gastrointestinal tract, and patient compliance is better.
[0005] In summary, most traditional Chinese medicine treatments for gastrointestinal dysfunction in patients undergoing chemotherapy for gastric cancer are oral decoctions, while there are no literature reports on topical traditional Chinese medicine combinations for treating gastrointestinal dysfunction in patients with advanced gastric cancer. Summary of the Invention
[0006] In view of the above-mentioned shortcomings of the prior art, according to embodiments of the present invention, it is desirable to provide a traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer, and to propose the use of the traditional Chinese medicine composition.
[0007] According to an embodiment, the present invention provides a traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer. The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 9-15 parts of Inula japonica, 9-15 parts of Zingiber officinale, 3-9 parts of Syzygium aromaticum, 6-15 parts of Dioscorea opposita, 6-15 parts of Dalbergia odorifera, 15-20 parts of Areca catechu, 15-20 parts of Areca peel, 15-20 parts of Lindera strychnifolia, 20-30 parts of Raphanus sativus, 15-20 parts of Citrus aurantium, and 9-15 parts of processed Rheum palmatum.
[0008] As a preferred example, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 9 parts of Inula japonica, 9 parts of Zingiber officinale, 6 parts of Clove, 9 parts of Persimmon calyx, 9 parts of Dalbergia odorifera, 15 parts of Areca catechu, 15 parts of Areca peel, 15 parts of Lindera strychnifolia, 25 parts of Radish seed, 15 parts of Citrus aurantium, and 9 parts of processed Rheum palmatum.
[0009] Furthermore, the traditional Chinese medicine composition is a topical medicine.
[0010] Furthermore, the topical medication is an acupoint patch.
[0011] Acupoint application is a non-invasive acupoint therapy based on the theory of meridians in Traditional Chinese Medicine. It involves grinding medicinal herbs into a fine powder, mixing them with a solvent to form a paste, or preparing them into ointments, pills, or cakes; or boiling traditional Chinese medicine decoctions into a paste; or spreading the powdered medicine onto a paste, and then directly applying it to acupoints. It works through multiple links and pathways, and is essentially a composite treatment method integrating meridians, acupoints, and medicine.
[0012] According to the embodiments, this invention uses external application of traditional Chinese medicine to treat gastrointestinal dysfunction in gastric cancer patients undergoing chemotherapy, selecting the acupoints Shenque (CV8), Neiguan (PC6), and Zusanli (ST36). Shenque (CV8) is a key acupoint on the Ren meridian, crucial for the flow of essence, qi, spirit, and blood. It has the effects of strengthening the spleen and stomach, warming yang and consolidating the body's foundation, and nourishing the original qi. Through acupoint application and other methods, it can improve symptoms such as hiccups, abdominal pain, and abdominal distension. Neiguan (PC6) belongs to the Pericardium meridian of Hand Jueyin. This acupoint is where the eight extraordinary meridians converge at Yinwei. Yinwei diseases affect the internal organs, and this acupoint is effective in treating visceral diseases, mainly treating stomach pain, vomiting, and hiccups. Zusanli (ST36) is one of the main acupoints on the Stomach meridian of Foot Yangming. It has the effects of drying spleen dampness and generating stomach qi, mainly treating digestive dysfunction such as stomach pain, vomiting, hiccups, abdominal distension, and constipation.
[0013] Subsequent examples will demonstrate that the herbal composition acupoint application of the present invention (hereinafter also referred to as the anti-diarrheal and abdominal-clearing application) uses a self-formulated prescription (Inula japonica 9g, Zingiber officinale 9g, Clove 6g, Persimmon calyx 9g, Dalbergia odorifera 9g, Areca catechu 15g, Areca peel 15g, Lindera strychnifolia 15g, Radish seed 25g, Citrus aurantium 15g, and Rhubarb 9g). In the prescription, Inula japonica, Zingiber officinale, Clove 6g, and Persimmon calyx 9g lower qi and resolve phlegm, and relieve hiccups; Dalbergia odorifera can invigorate blood and relieve pain, and lower qi and eliminate foulness; Areca catechu, Areca peel, Lindera strychnifolia, and Citrus aurantium can regulate qi and promote circulation, resolve phlegm and eliminate lumps; Radish seed and Rhubarb 9g can promote digestion and relieve bloating, and purge accumulations; The whole prescription works together to relieve hiccups, regulate qi and promote circulation, and purge accumulations, and has a good therapeutic effect on gastrointestinal dysfunction in patients undergoing chemotherapy for gastric cancer. Detailed Implementation
[0014] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading the description of this invention, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.
[0015] Example 1
[0016] Ingredients: 9g of Inula japonica, 9g of Zingiber officinale, 6g of Clove, 9g of Persimmon Calyx, 9g of Dalbergia odorifera, 15g of Areca catechu, 15g of Areca peel, 15g of Lindera strychnifolia, 25g of Radish seed, 15g of Citrus aurantium, and 9g of Rheum palmatum. Grind the above-mentioned herbs into powder, mix them evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and make pills with a diameter of about 1cm on a pill-making machine. Package for later use.
[0017] Example 2
[0018] Ingredients: 12g Inula japonica, 9g Zingiber officinale, 6g Clove, 6g Persimmon calyx, 6g Dalbergia odorifera, 20g Areca catechu, 15g Areca peel, 15g Lindera strychnifolia, 20g Radish seed, 15g Citrus aurantium, 9g Rheum palmatum (processed). Grind the above ingredients into powder, mix evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and make into pills with a diameter of about 1cm on a pill-making machine. Package for later use.
[0019] Example 3
[0020] Ingredients: 15g Inula japonica, 9g Zingiber officinale, 3g Clove, 6g Persimmon calyx, 6g Dalbergia odorifera, 15g Areca catechu, 20g Areca peel, 15g Lindera strychnifolia, 30g Radish seed, 20g Citrus aurantium, 12g Rheum palmatum (processed). Grind the above ingredients into powder, mix evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and form into pills with a diameter of about 1cm on a pill-making machine. Package for later use.
[0021] Example 4
[0022] Ingredients: 12g Inula japonica, 12g Zingiber officinale, 3g Clove, 6g Persimmon calyx, 9g Dalbergia odorifera, 15g Areca catechu, 15g Areca peel, 15g Lindera strychnifolia, 20g Radish seed, 15g Citrus aurantium, 9g Rheum palmatum (processed). Grind the above ingredients into powder, mix evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and make into pills with a diameter of about 1cm on a pill-making machine. Package for later use.
[0023] Example 5
[0024] Ingredients: 15g Inula japonica, 9g Zingiber officinale, 6g Clove, 6g Persimmon calyx, 12g Dalbergia odorifera, 18g Areca catechu, 18g Areca peel, 15g Lindera strychnifolia, 25g Radish seed, 15g Citrus aurantium, 12g Rheum palmatum (processed). Grind the above ingredients into powder, mix evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and form into pills with a diameter of about 1cm on a pill-making machine. Package for later use.
[0025] Example 6
[0026] 9g of Inula japonica, 9g of Zingiber officinale, 9g of Clove, 9g of Persimmon Calyx, 12g of Dalbergia odorifera, 15g of Areca catechu, 15g of Areca peel, 20g of Lindera strychnifolia, 30g of Radish seed, 20g of Citrus aurantium, and 15g of Rheum palmatum. Grind the above-mentioned herbs into powder, mix them evenly, sterilize, mix the powder with an appropriate amount of Vaseline, and make pills with a diameter of about 1cm on a pill-making machine. Package them for later use.
[0027] Example 7 - Clinical efficacy analysis of anti-rebellious and abdominal-clearing plaster
[0028] 1. Research Materials and Methods
[0029] 1.1 Case Data
[0030] The study included 72 patients with advanced gastric cancer who underwent chemotherapy at the Oncology Department of Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine between January 2021 and December 2023. All enrolled patients were informed of the study and voluntarily participated in and cooperated with the clinical observation. All patients were randomly assigned to two groups using a random number table: a treatment group (treated with Jiangni Tong Fu plaster) (n=38) and a control group (n=34). There were no statistically significant differences in general characteristics between the two groups (P>0.05).
[0031] 1.2 Diagnostic criteria
[0032] TNM staging for gastric cancer: Follows the American Journal of Cancer (AJCC / UICC) staging manual, 8th edition. Diagnostic criteria for gastrointestinal dysfunction are based on the "Guiding Principles for Clinical Research of New Traditional Chinese Medicine" and "Modern Traditional Chinese Medicine Oncology," with epigastric fullness as the primary symptom, combined with relevant symptoms related to gastrointestinal function to determine the diagnostic criteria.
[0033] 1.3 Inclusion Criteria
[0034] (1) Patients diagnosed with advanced gastric cancer by pathology and who have received chemotherapy;
[0035] (2) Age 18 ≤ 70 years, gender not limited;
[0036] (3) Expected survival ≥ 6 months, Exercising Performance Status (ECOG) score ≤ 2;
[0037] (4) Agree to follow-up and anti-diarrheal abdominal patch treatment; have complete follow-up and clinical medical records; and voluntarily sign the informed consent form.
[0038] 1.4 Exclusion Criteria
[0039] (1) Patients who are pregnant, breastfeeding, or planning to become pregnant;
[0040] (2) Individuals allergic to the drugs or their components used in this study;
[0041] (3) Patients with serious heart, brain, liver, kidney diseases or mental illness;
[0042] (4) Patients with a history of multiple cancers;
[0043] (5) There is a serious or difficult-to-control infection;
[0044] 1.5 Rejection Criteria
[0045] (1) Those with poor compliance or who voluntarily withdraw from this study are considered dropout cases;
[0046] (2) Serious adverse events are included in the adverse reaction statistics;
[0047] (3) Those that fall off spontaneously due to ineffectiveness should be included in the efficacy analysis;
[0048] (4) Cases included that did not take medication as prescribed, had insufficient treatment courses, or had incomplete case reports.
[0049] 2 Research Methods
[0050] 2.1 Treatment methods
[0051] Control group: In accordance with the 2020 NCCN (National Comprehensive Cancer Network) Palliative Care Guidelines and the "New Guidelines for the Diagnosis and Treatment of Common Malignant Tumors (Cancer Pain Control and Palliative Care)", patients were treated symptomatically with granisetron, metoclopramide, omeprazole, lactulose, etc., based on their clinical symptoms, but no immunomodulatory drugs were used.
[0052] Treatment group: In addition to the treatment given to the control group, the following Chinese herbs were weighed: 9g of Inula japonica, 9g of Zingiber officinale, 6g of Syzygium aromaticum, 9g of Dioscorea opposita, 9g of Dalbergia odorifera, 15g of Areca catechu, 15g of Areca peel, 15g of Lindera strychnifolia, 25g of Raphanus sativus, 15g of Citrus aurantium, and 9g of processed Rheum palmatum. These herbs were ground into powder, mixed evenly, sterilized, and then mixed with an appropriate amount of Vaseline. The mixture was then made into pills approximately 1cm in diameter using a pill-making machine and packaged for later use. On the day of chemotherapy, after routine disinfection of acupoints (Shenque acupoint, bilateral Zusanli acupoints, and bilateral Neiguan acupoints), the pills were applied to the acupoints and secured with hypoallergenic adhesive tape. This was done once daily for 8-12 hours. One week of continuous application constituted one course of treatment.
[0053] 2.2 Observation Indicators
[0054] ① Traditional Chinese Medicine Symptom Scoring
[0055] Following the efficacy evaluation criteria of the "Guiding Principles for Clinical Research of New Traditional Chinese Medicines," the gastrointestinal function symptom scores of the two groups of patients after one course of treatment were observed. Based on the principle of grading and quantification, primary symptoms included epigastric distension, loss of appetite, nausea, and vomiting; secondary symptoms included lethargy, shortness of breath, vomiting clear fluid, epigastric discomfort, belching, acid reflux, constipation, loose stools, and dry stools. Primary symptoms were assigned scores of 0, 2, 4, and 6 respectively for absence, mild, moderate, and severe; secondary symptoms were assigned scores of 0, 1, 2, and 3 respectively for absence, mild, moderate, and severe. Based on the "Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs," the following TCM syndrome efficacy evaluation criteria were established: Clinically cured: symptoms and signs disappear, efficacy index ≥ 90%; Significantly effective: symptoms and signs basically disappear, 60% ≤ efficacy index < 90%; Effective: symptoms and signs are alleviated, 30% ≤ efficacy index < 60%; Ineffective: symptoms and signs do not alleviate, or even worsen, efficacy index < 90%. The efficacy index was calculated based on the scores of the main symptoms before and after treatment, using the nimodipine symptom scoring method. Formula: Efficacy index = [(Total symptom score before treatment - Total symptom score after treatment) ÷ Total symptom score before treatment] × 100%.
[0056] ② Quality of life
[0057] The Quality of Life Scale (QOL) for Cancer Patients is a commonly used scale in my country for assessing the quality of life of cancer patients. It consists of 12 items, each divided into 5 levels, with scores ranging from 1 to 5. The maximum score for quality of life is 60 points, with 51-60 points for good, 41-50 points for relatively good, 31-40 points for average, 21-30 points for poor, and <20 points for very poor.
[0058] 3. Statistical Analysis
[0059] The chi-square test and t-test were used to compare the sample means between the two groups. The results are expressed as (x±s). P<0.05 was considered statistically significant.
[0060] 4. Research Results
[0061] 4.1 Comparison of TCM symptom scores before and after treatment
[0062] Before and after treatment, the anti-nausea and vomiting patch effectively improved gastrointestinal symptoms (nausea and vomiting, constipation, diarrhea), and the difference was statistically significant (P<0.01). Compared with the control group, the treatment group showed more significant improvement and was superior to the control group (P<0.05).
[0063] Table 1. Comparison of TCM syndrome scores before and after treatment
[0064] Group Number of examples Before treatment After treatment Treatment group 38 23.89±0.77 <![CDATA[19.53±0.58 *# ]]> control group 34 23.76±0.84 21.29±0.67
[0065] Note: Compared with before treatment, *P < 0.01, intergroup comparison after treatment # P < 0.05.
[0066] 4.2 Comparison of quality of life scale before and after treatment.
[0067] Before and after treatment, the anti-rebellious and abdominal plaster significantly improved the quality of life of patients, and the difference was statistically significant (P<0.01). Compared with the control group, the treatment group showed more significant improvement and was superior to the control group (P<0.05).
[0068] Table 2. Comparison of Quality of Life (QOL) scores before and after treatment
[0069] Group Number of examples Before treatment After treatment Treatment group 38 41.47±0.71 <![CDATA[46.08±0.61 *# ]]> control group 34 41.18±0.78 43.97±0.82
[0070] Note: Compared with before treatment, * P < 0.01, intergroup comparison after treatment # P < 0.05.
[0071] Example 8 (Animal Experiment)
[0072] 1. Materials and Methods
[0073] 1.1 Drugs and Reagents
[0074] Preparation of the traditional Chinese medicine composition of the present invention: prepared according to Example 1.
[0075] Preparation of the control group's traditional Chinese medicine composition: In the following proportions by weight, 2g of Inula japonica, 2g of Zingiber officinale, 1g of Syzygium aromaticum, 2g of Persimmon calyx, 2g of Dalbergia odorifera, 3g of Areca catechu, 3g of Areca peel, 3g of Lindera strychnifolia, 5g of Radish seed, 3g of Citrus aurantium, and 2g of processed Rheum palmatum were ground into powder, mixed evenly, sterilized, and the powder was mixed evenly with an appropriate amount of Vaseline. The mixture was then made into pills with a diameter of about 1cm on a pill-making machine and packaged for later use.
[0076] Main reagents: Fluorouracil injection (Shanghai Xudong Haipu Pharmaceutical Co., Ltd.); physiological saline (Shanghai Yansheng Industrial Co., Ltd.); N-nitrosodiethylamine (Shanghai Puzhen Biotechnology Co., Ltd.); gastrin (GAS), rat motilin (MTL), and vasoactive intestinal peptide (VIP) ELISA kit (provided by Nanjing Jiancheng Technology Co., Ltd.).
[0077] 1.2 Animals
[0078] SPF-grade SD rats, weighing 80-100g, 60 rats in total, half male and half female, were provided by Shanghai Slack Laboratory Animal Service Co., Ltd.
[0079] 1.3 Main Instruments
[0080] Electronic balance (Mettler Toledo AG, Switzerland); centrifuge (Beijing Medical Centrifuge Factory); syringe (BD Medical Devices).
[0081] 2. Methods and Results
[0082] 2.1 Animal Model Establishment and Grouping
[0083] Sixty rats were randomly divided into four groups: a blank control group, a model group, a patch treatment group, and a control group, with 15 rats in each group. The blank control group was fed normally, while the remaining three groups were used to establish a gastric cancer model. After fasting for 24 hours, the rats were given N-nitrosodiethylamine (DENA) at 2.8 mg / kg for 80 consecutive days to induce a gastric cancer model. After successful modeling, the rats underwent chemotherapy, receiving fluorouracil injection at a dose of 20 mg / kg via intraperitoneal injection, 0.2 ml each time, once a day for 7 consecutive days. During chemotherapy, the acupoints of the rats were located according to the "Experimental Acupuncture" and the rat acupoint atlas. Based on the principle of analogy, the hair at acupoints such as Shenque, Neiguan, and Zusanli of the modeled rats was removed and residual hair was washed away before the rats were grouped and treated.
[0084] 2.2 Grouped administration
[0085] Control group: Normal feeding, no treatment.
[0086] Model group: After the fluorouracil administration was completed, the patient was given normal saline by gavage daily.
[0087] Application group: Using the traditional Chinese medicine composition of the present invention (prepared according to Example 1), rats were bound to a rat board, and after the acupoints were located and the hair was shaved, the prepared application cake was fixed on the acupoints with desensitizing adhesive tape. The binding was carried out for 6 hours, and the drug was administered continuously for 7 days, and physiological saline was also administered orally.
[0088] Control group: The rats were bound to a rat board using the aforementioned control group Chinese medicine composition. After the acupoints were located and the hair was shaved, the prepared control patch was fixed to the acupoints with desensitizing adhesive tape. The rats were bound for 6 hours and administered the medicine for 7 consecutive days, and were also given physiological saline by gavage.
[0089] 2.3 Specimen Collection and Processing
[0090] After the experiment, the patient fasted for 24 hours and was anesthetized by intraperitoneal injection of 4 mL / kg of 20% urethane. Blood was collected from the abdominal aorta and left at room temperature for 2-3 hours. The blood was then centrifuged at 3000 r / min for 15 minutes at 4℃. The supernatant was collected and stored at -20℃ for later analysis.
[0091] 2.4 Evaluation Index Testing
[0092] (1) General condition observation: Daily observation of the rat's mental state, posture, fur color, activity level, responsiveness to restraint, color of the eyelid mucosa, and feces, etc.
[0093] (2) The levels of gastrin (GAS), motilin (MTL), and vasoactive intestinal peptide (VIP) in rat plasma were detected using an ELISA kit.
[0094] (3) Gastric emptying and small intestinal propulsion experiments were conducted using a semi-solid rice paste method, and the gastric emptying rate and small intestinal propulsion rate of rats were calculated. (Xing Jianfeng, Feng Weiyi, Hou Jiayu. Discussion on experimental methods for gastric emptying and small intestinal propulsion in mice. Journal of Beijing University of Traditional Chinese Medicine, 2003; 26: 50-52)
[0095] 2.5 Statistical Analysis
[0096] Data were processed using SPSS 16.0 software. All continuous data were expressed as sample size (n) and mean ± SD. Normality and homogeneity of variance were tested for all data. For data meeting normality, one-way ANOVA was used for multiple groups of continuous data; the LSD test was used when variances were homogeneous, and the Dunnett T3 test was used when variances were unequal. The rank-sum test was used when normality was not met. A p-value < 0.05 was considered statistically significant.
[0097] 2.6 Results
[0098] 2.6.1 Observation of the general condition of rats in each group
[0099] Before the experiment, rats in all groups were in good spirits, active, with glossy fur, and produced spherical feces of moderate consistency. After modeling, rats in the model group became lethargic, listless, with dull, yellowish fur, drooping whiskers, huddled together or hibernating in corners, and produced loose stools. Rats in the application group showed improved spirits compared to the model group, increased activity, cleaner fur, and drier feces. There was no significant difference between the control group and the model group. The body weight of rats in each group after the drug administration was shown in Table 3. Compared to the control group, the body weight of rats in the model group was significantly lower (P < 0.001); while compared to the model group, the body weight of rats in the application group was significantly higher (P < 0.05), and there was no significant difference in body weight in the control group (P > 0.05).
[0100] Table 3. Changes in body weight of rats in each group
[0101] Group Body weight (at the end of administration) / g Blank group 182.85±2.11 Model group <![CDATA[147.38±4.47 1) ]]> Application group <![CDATA[163.36±2.88 1)2)3) ]]> control group <![CDATA[149.05±5.23 1) ]]>
[0102] Note: Compared with the blank group 1) (P < 0.001); compared with the model group 2) (P < 0.05), compared with the control group 3) (P < 0.05).
[0103] 2.6.2 Levels of gastrin (GAS), motilin (MTL), and vasoactive intestinal peptide (VIP) in the plasma of rats in each group
[0104] The levels of GAS, MTL, and VIP in rat plasma are shown in Table 4. Compared with the blank group, the levels of GAS and MTL in the model group were significantly decreased (P<0.05, P<0.01), and the level of VIP was significantly increased (P<0.05). Compared with the model group, the levels of GAS and MTL in the plasma of the patch group were significantly increased, and the level of VIP was significantly decreased (P<0.05). Compared with the model group, there was no significant difference in the levels of GAS, MTL, and VIP in the plasma of the control group.
[0105] Table 4. Content of GAS, MTL and VIP in rats of each group
[0106] Group GAS / (pg / mL) MTL / (pg / mL) VIP / (pg / mL) Blank group 61.60±2.38 118.11±4.46 31.81±1.70 Model group <![CDATA[49.01±2.05 1) ]]> <![CDATA[95.13±4.42 3) ]]> <![CDATA[36.53±1.29 1) ]]> Application group <![CDATA[55.60±2.16 2) ]]> <![CDATA[107.12±3.59 2) ]]> <![CDATA[32.27±1.58 2) ]]> control group 49.67±1.89 97.47±4.32 35.87±1.27
[0107] Note: Compared with the blank group 1) (P < 0.05) 3) (P < 0.01); compared with the model group 2) (P < 0.05).
[0108] 2.6.3 Comparison of gastrointestinal motility in rats of different groups
[0109] The comparison results of gastrointestinal motility in rats of different groups are shown in Table 5. Compared with the blank group, the gastric emptying rate and small intestinal propulsion rate of the model group were significantly decreased (P < 0.001); compared with the model group, the gastric emptying rate and small intestinal propulsion rate of the patch group were significantly increased (P < 0.005) and significantly increased (P < 0.01). Compared with the model group, there was no significant difference in gastric emptying rate and small intestinal propulsion rate in the control group.
[0110] Table 5. Comparison of gastrointestinal motility in rats
[0111] Group Gastric emptying rate / % Small intestine propulsion rate / % Blank group 71.07±1.35 72.33±2.18 Model group <![CDATA[59.13±1.62 1) ]]> <![CDATA[61.01±1.90 1) ]]> Application group <![CDATA[67.20±1.95 2) ]]> <![CDATA[68.67±2.25 3) ]]> control group 60.53±1.70 62.07±2.24
[0112] Note: Compared with the blank group 1) (P < 0.001); compared with the model group 2) (P < 0.005) 3) (P < 0.01).
[0113] In summary, the herbal composition of the present invention applied to the treatment group has the effect of improving gastrointestinal dysfunction in rats undergoing chemotherapy for gastric cancer to varying degrees.
Claims
1. A traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer, characterized in that, The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 9-15 parts of Inula japonica, 9-15 parts of Zingiber officinale, 3-9 parts of Syzygium aromaticum, 6-15 parts of Dioscorea opposita, 6-15 parts of Dalbergia odorifera, 15-20 parts of Areca catechu, 15-20 parts of Areca peel, 15-20 parts of Lindera strychnifolia, 20-30 parts of Raphanus sativus, 15-20 parts of Citrus aurantium, and 9-15 parts of processed rhubarb. The traditional Chinese medicine composition is made into an acupoint patch and applied to the Shenque acupoint, bilateral Zusanli acupoints, and bilateral Neiguan acupoints.
2. The traditional Chinese medicine composition according to claim 1, characterized in that, The raw materials are in the following weight proportions: 9 parts of Inula japonica, 9 parts of Zingiber officinale, 6 parts of Clove, 9 parts of Persimmon Calyx, 9 parts of Dalbergia odorifera, 15 parts of Areca catechu, 15 parts of Areca peel, 15 parts of Lindera strychnifolia, 25 parts of Radish seed, 15 parts of Citrus aurantium, and 9 parts of Rheum palmatum.
3. Use of the traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating gastrointestinal dysfunction during chemotherapy for gastric cancer.
4. The use according to claim 3, characterized in that, The Chinese herbal decoction is boiled into a paste, or the powdered medicine is sprinkled on a plaster and then applied directly to the Shenque acupoint, the bilateral Zusanli acupoint, and the bilateral Neiguan acupoint.
Citation Information
Patent Citations
Traditional Chinese medicine composition for treating critical gastrointestinal dysfunction and preparation method thereof
CN113209205A
